ACAD — ACADIA PHARMACEUTICALS INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ACAD
| date | signal | measured base rate |
|---|---|---|
| 2026-08-10 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-05 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-28 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-25 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-19 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Open-market sale 10b5-1 plan | 9.3K | 29.34 | 272.6K |
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 14.3K | 17.84 | 255.0K |
| 2026-08-06 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Open-market sale 10b5-1 plan | 5.0K | 29.00 | 145.0K |
| 2026-08-05 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Open-market sale 10b5-1 plan | 5.8K | 29.00 | 169.6K |
| 2026-08-05 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 5.8K | 17.84 | 104.3K |
| 2026-07-30 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Open-market sale 10b5-1 plan | 16.5K | 26.13 | 431.4K |
| 2026-07-30 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Open-market sale 10b5-1 plan | 50 | 26.17 | 1.3K |
| 2026-07-29 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Option exercise | 32.3K | — | — |
| 2026-06-26 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Open-market sale 10b5-1 plan | 11.4K | 26.08 | 297.9K |
| 2026-05-29 | BAKER JULIAN Director | Grant or award | 18.6K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BAKER BROS. ADVISORS LP | 954.9M | 42.9M |
| BlackRock, Inc. | 479.7M | 21.6M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 193.0M | 8.7M |
| STATE STREET CORP | 185.5M | 8.3M |
| RTW INVESTMENTS, LP | 159.0M | 7.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 126.0M | 5.7M |
| GEODE CAPITAL MANAGEMENT, LLC | 77.1M | 3.5M |
| FIRST TRUST ADVISORS LP | 74.4M | 3.3M |
| DIMENSIONAL FUND ADVISORS LP | 70.2M | 3.2M |
| Palo Alto Investors LP | 63.9M | 2.9M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript · 2026-08-12
- ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued - simplywall.st · 2026-08-11 · simplywall.st
- ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued - simplywall.st · 2026-08-11 · simplywall.st
Ask the AI about ACAD
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →